

Reverse Phase Protein Array (RPPA) Research Publications

Pierobon M, Petricoin EF 3rd, Wulfschlegel JD. Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future. *Expert Rev Proteomics*. 2018 Oct 10:1-3.

<https://doi.org/10.1080/14789450.2018.1531709>

Cruickshanks N, Zhang Y, Hine S, Gibert M, Yuan F, Oxford M, Grello CM, Pahuski M, Dube C, Guessous F, Wang B, Deveau C, Saoud K, Gallagher RI, Wulfschlegel JD, Schiff D, Phan SC, Petricoin EF, Abounader R. Discovery and therapeutic exploitation of mechanisms of resistance to MET inhibitors in glioblastoma. *Clin Cancer Res*. 2018 Sep 10.

<https://doi.org/10.1158/1078-0432.CCR-18-0926>

deCarvalho AC, Kim H, Poisson LM, Winn ME, Mueller C, Cherba D, Koeman J, Seth S, Protopopov A, Felicella M, Zheng S, Multani A, Jiang Y, Zhang J, Nam DH, Petricoin EF, Chin L, Mikkelsen T, Verhaak RGW. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. *Nat Genet*. 2018 Apr 23.

<https://doi.org/10.1038/s41588-018-0105-0>

Pollmann SE, Calvert VS, Rao S, Boca SM, Madhavan S, Horak ID, Kjaer A, Petricoin EF, Kragh M, Poulsen TT. Acquired resistance to a MET antibody in vivo can be overcome by the MET antibody mixture Sym015. *Mol Cancer Ther*. 2018 Mar 15.

<https://doi.org/10.1158/1535-7163.MCT-17-0787>

Blohm-Mangone K, Burkett NB, Tahsin S, Myrdal PB, Aodah A, Ho B, Janda J, McComas M, Saboda K, Roe DJ, Dong Z, Bode AM, Petricoin EF, Calvert VS, Curiel-Lewandrowski C, Alberts DS, Wondrak GT, Dickinson SE. Pharmacological TLR4 antagonism using topical resatorvid blocks solar UV-induced skin tumorigenesis in SKH-1 mice. *Cancer Prev Res*. 2018 Feb 1.

<https://doi.org/10.1158/1940-6207.CAPR-17-0349>

de la Fuente C, Pinkham C, Dabbagh D, Beitzel B, Garrison A, Palacios G, Hodge KA, Petricoin EF, Schmaljohn C, Campbell CE, Narayanan A, Kehn-Hall K. Phosphoproteomic analysis reveals Smad protein family activation following Rift Valley fever virus infection. *PLoS One*. 2018 Feb 6;13(2).

<https://doi.org/10.1371/journal.pone.0191983>

Ding KF, Petricoin EF, Finlay D, Yin H, Hendricks WPD, Sereduk C, Kiefer J, Sekulic A, LoRusso PM, Vuori K, Trent JM, Schork NJ. Nonlinear mixed effects dose response modeling in high throughput drug screens: application to melanoma cell line analysis. *Oncotarget*. 2017 Dec 15;9(4):5044-5057.

<https://doi.org/10.18632/oncotarget.23495>

Tricoli L, Naeem A, Parasido E, Mikhael JP, Choudhry MU, Berry DL, Abdelgawad IA, Lee RJ, Feldman AS, Ihemelandu C, Avantaggiati M, Kumar D, Byers S, Gallagher R, Wulfkühle J, Petricoin E, Rodriguez O, Albanese C. Characterization of the effects of defined, multidimensional culture conditions on conditionally reprogrammed primary human prostate cells. *Oncotarget*. 2017 Dec 18;9(2):2193-2207.
<https://doi.org/10.18632/oncotarget.23363>

Ludovini V, Chiari R, Tomassoni L, Antonini C, Baldelli E, Baglivo S, Siggillino A, Tofanetti FR, Bellezza G, Hodge KA, Petricoin E, Pierobon M, Crinò L, Bianconi F. Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non-small cell lung cancer (NSCLC): a pilot study. *Oncotarget*. 2017 Jun 14;8(47):83343-83353.
<https://doi.org/10.18632/oncotarget.18480>

Guo Z, Sevrioukova IF, Denisov IG, Zhang X, Chiu TL, Thomas DG, Hanse EA, Cuellar RAD, Grinkova YV, Langenfeld VW, Swedien DS, Stamschror JD, Alvarez J, Luna F, Galván A, Bae YK, Wulfkühle JD, Gallagher RI, Petricoin EF 3Rd, Norris B, Flory CM, Schumacher RJ, O'Sullivan MG, Cao Q, Chu H, Lipscomb JD, Atkins WM, Gupta K, Kelekar A, Blair IA, Capdevila JH, Falck JR, Sligar SG, Poulos TL, Georg GI, Ambrose E, Potter DA. Heme Binding Biguanides Target Cytochrome P450-Dependent Cancer Cell Mitochondria. *Cell Chem Biol*. 2017 Oct 19;24(10):1314.
<https://doi.org/10.1016/j.chembiol.2017.08.009>

Jayappa KD, Portell CA, Gordon VL, Capaldo BJ, Bekiranov S, Axelrod MJ, Brett LK, Wulfkühle JD, Gallagher RI, Petricoin EF, Bender TP, Williams ME, Weber MJ. Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL. *Blood Adv*. 2017 Jun 13;1(14):933-946.
<https://dx.doi.org/10.1182%2Fbloodadvances.2016004176>

Rao G, Pierobon M, Kim IK, Hsu WH, Deng J, Moon YW, Petricoin EF, Zhang YW, Wang Y, Giaccone G. Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. *Sci Rep*. 2017 Aug 1;7(1):7066.
<https://doi.org/10.1038/s41598-017-06128-9>

Varghese RS, Zuo Y, Zhao Y, Zhang YW, Jablonski SA, Pierobon M, Petricoin EF, Ressonm HW, Weiner LM. Protein network construction using reverse phase protein array data. *Methods*. 2017 Jul 15;124:89-99
<https://doi.org/10.1016/j.ymeth.2017.06.017>

Zhang Y, Cruickshanks N, Yuan F, Wang B, Pahuiski M, Wulfkühle J, Gallagher I, Koeppel AF, Hatfeg S, Papanicolas C, Lee J, Bar EE, Schiff D, Turner S, Petricoin EF, Gray LS, Abounader R. Targetable T-type calcium channels drive glioblastoma. *Cancer Res*. 2017 May 16.
<https://doi.org/10.1158/0008-5472.CAN-16-2347>

Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle JD, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK. Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer. *Mol Cancer Ther.* 2017 May 3. [Epub ahead of print]
<https://doi.org/10.1158/1535-7163.MCT-17-0111>

Simbulan-Rosenthal CM, Dakshanamurthy S, Gaur A, Chen YS, Fang HB, Abdussamad M, Zhou H, Zapas J, Calvert V, Petricoin EF, Atkins MB, Byers SW, Rosenthal DS. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma. *Oncotarget.* 2017 Feb 2. doi: 10.18632/oncotarget.14990. [Epub ahead of print]
<https://doi.org/10.18632/oncotarget.14990>

Brody JR, Yabar CS, Zarei M, Bender J, Matrisian LM, Rahib L, Heartwell C, Mason K, Yeo CJ, Peiper SC, Jiang W, Varieur K, Madhavan S, Petricoin E 3rd, Fortuna D, Curtis M, Wang ZX, Pishvaian MJ, Winter JM. Identification of a novel metabolic-related mutation (IDH1) in metastatic pancreatic cancer. *Cancer Biol Ther.* 2016 Jul 28:0.
<https://doi.org/10.1080/15384047.2016.1210743>

Dickinson SE, Janda J, Criswell J, Blohm-Mangone K, Olson ER, Liu Z, Barber C, Rusche JJ, Petricoin E 3rd, Calvert V, Einspahr JG, Dickinson JE, Stratton SP, Curiel-Lewandrowski C, Saboda K, Hu C, Bode AM, Dong Z, Alberts DS, Bowden GT. Inhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin. *Cancer Prev Res.* 2016 2016 Mar;9(3):215-24
<https://doi.org/10.1158/1940-6207.CAPR-15-0419>

Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ. Long-term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. *Cancer Cell.* 2016 Jan 11;29(1):75-89
<https://doi.org/10.1016/j.ccell.2015.11.011>

Roller DG, Capaldo B, Bekiranov S, Mackey AJ, Conaway MR, Petricoin EF, Gioeli D, Weber MJ. Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. *Oncotarget.* 2015 Dec 10.
<https://doi.org/10.18632/oncotarget.6548>

Budd WT, Seashols-Williams SJ, Clark GC, Weaver D, Calvert V, Petricoin E, Dragoescu EA, O'Hanlon K, Zehner ZE. Dual Action of miR-125b As a Tumor Suppressor and OncomiR-22 Promotes Prostate Cancer Tumorigenesis. *PLoS One.* 2015 Nov 6;10(11).
<https://doi.org/10.1371/journal.pone.0142373>

Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S. Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. *PLoS One*. 2015 Sep 25;10(9):e0138210.

<https://doi.org/10.1371/journal.pone.0138210>

Blanco FF, Jimbo M, Wulfkuhle J, Gallagher I, Deng J, Enyenihi L, Meisner-Kober N, Londin E, Rigoutsos I, Sawicki JA, Risbud MV, Witkiewicz AK, McCue PA, Jiang W, Rui H, Yeo CJ, Petricoin E, Winter JM, Brody JR. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells. *Oncogene*. 2015 Sep 21. doi: 10.1038/onc.2015.325.

<https://doi.org/10.1038/onc.2015.325>

LeBlanc FR, Liu X, Hengst J, Fox T, Calvert V, Petricoin EF 3rd, Yun J, Feith DJ, Loughran TP Jr. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia. *Cancer Biol Ther*. 2015 Aug 7:0. [Epub ahead of print]

<https://doi.org/10.1080/15384047.2015.1078949>

Zhang YW, Nasto RE, Varghese R, Jablonski SA, Serebriiskii IG, Surana R, Calvert VS, Bebu I, Murray J, Jin L, Johnson M, Riggins R, Ransom H, Petricoin E, Clarke R, Golemis EA, Weiner LM. Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. *Oncogene*. 2015 Jul 13. doi: 10.1038/onc.2015.226.

<https://doi.org/10.1038/onc.2015.226>

Bermudez Y, Stratton SP, Curiel-Lewandrowski C, Warneke JA, Hu C, Bowden GT, Dickinson SE, Dong Z, Bode AM, Saboda K, Brooks C, Petricoin E 3rd, Hurst C, Alberts DS, Einspahr JG. Activation of the PI3K/Akt/mTOR and MAP kinase Signaling Pathways in Response to Acute Solar Simulated Light Exposure of Human Skin. *Cancer Prev Res* 2015 Aug;8(8):720-8

<https://dx.doi.org/10.1158%2F1940-6207.CAPR-14-0407>

Alem F, Yao K, Lane D, Calvert V, Petricoin EF, Kramer L, Hale ML, Bavari S, Panchal RG, Hakami RM. Host response during *Yersinia pestis* infection of human bronchial epithelial cells involves negative regulation of autophagy and suggests a modulation of survival-related and cellular growth pathways. *Front Microbiol*. 2015 Feb 13;6:50

<https://doi.org/10.3389/fmicb.2015.00050>

Ligaba SB, Khurana A, Graham G, Krawczyk E, Jablonski S, Petricoin EF, Glazer RI, Upadhyay G. Multifactorial analysis of conditional reprogramming of human keratinocytes. *PLoS One*. 2015 Feb 25;10(2)

<https://doi.org/10.1371/journal.pone.0116755>

Falchi M, Varricchio L, Martelli F, Masiello F, Federici G, Zingariello M, Girelli G, Whitsett C, Petricoin EF, Moestrup SK, Zeuner A, Migliaccio AR. Dexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion. *Haematologica*. 2014 Dec 22.

<https://doi.org/10.3324/haematol.2014.114405>

Tian Y, Wang SS, Zhang Z, Rodriguez OC, Petricoin E 3rd, Shih IM, Chan D, Avantaggiati M, Yu G, Ye S, Clarke R, Wang C, Zhang B, Wang Y, Albanese C. Integration of network biology and imaging to study cancer phenotypes and responses. *IEEE/ACM Trans Comput Biol Bioinform*. 2014 Nov-Dec;11(6):1009-1019.

<https://dx.doi.org/10.1109%2FTCB.2014.2338304>

Voss K, Amaya M, Mueller C, Roberts B, Kehn-Hall K, Bailey C, Petricoin E 3rd, Narayanan A. Inhibition of host extracellular signal-regulated kinase (ERK) activation decreases new world alphavirus multiplication in infected cells. *Virology*. 2014 Sep 24;468-470C:490-503.

<https://doi.org/10.1016/j.virol.2014.09.005>

Mikkelsen T, deCarvalho AC, Arnold K, Mueller C, Petricoin EF 3rd, Poisson LM, Irtenkauf S, Hasselbach L. Cabozantinib is effective in a subset of xenograft gbm tumors and affects multiple signaling pathways. *Neuro Oncol*. 2014 Jul;16 Suppl 3:iii38.

<https://dx.doi.org/10.1093%2Fneuroonc%2Fnou208.58>

Signore M, Pelacchi F, di Martino S, Runci D, Biffoni M, Giannetti S, Morgante L, De Majo M, Petricoin EF, Stancato L, Larocca LM, De Maria R, Pallini R, Ricci-Vitiani L. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. *Cell Death Dis*. 2014 May 8;5:e1223.

<https://doi.org/10.1038/cddis.2014.188>

Liotta LA, Petricoin EF 3rd. Multiplex Proteomic Analysis of Cells in Fine Needle Aspiration Specimens: How Soon Can We Expect to Individualize Therapy by Comparing Pre- and Posttreatment Biopsies? *Clin Chem*. 2014 Apr 9.

<http://clinchem.aaccjnls.org/content/60/9/1143>

Amaya M, Voss K, Sampey G, Senina S, de la Fuente C, Mueller C, Calvert V, Kehn-Hall K, Carpenter C, Kashanchi F, Bailey C, Mogelsvang S, Petricoin E, Narayanan A. The Role of IKK β in Venezuelan Equine Encephalitis Virus Infection. *PLoS One*. 2014 Feb 19;9(2):e86745.

<https://doi.org/10.1371/journal.pone.0086745>

Salhia B, Kiefer J, Ross JT, Metapally R, Martinez RA, Johnson KN, Diperna DM, Paquette KM, Jung S, Nasser S, Wallstrom G, Tembe W, Baker A, Carpten J, Resau J, Ryken T, Sibenaller Z, Petricoin EF, Liotta LA, Ramanathan RK, Berens ME, Tran NL.

Integrated genomic and epigenomic analysis of breast cancer brain metastasis. *PLoS One*. 2014 Jan 29;9(1):e85448.

<https://doi.org/10.1371/journal.pone.0085448>

Lai C-H, Park K-S, Lee D-H, Alberobello AT, Raffeld M, Pierobon M, Pin E, Petricoin EF, Wang Y, Giaccone G. 2014. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. *Oncogene*. 2013 Oct 28. doi: 10.1038/onc.2013.439.

<https://doi.org/10.1038/onc.2013.439>

Federici G, Gao X, Slawek J, Arodz T, Shitaye A, Wulfkühle JD, De Maria R, Liotta LA, Petricoin EF 3rd. Systems Analysis Of The Nci-60 Cancer Cell Lines By Alignment Of Protein Pathway Activation Modules With "-Omic" Data Fields And Therapeutic Response Signatures. *Mol Cancer Res*. 2013 May 1.

<https://doi.org/10.1158/1541-7786.MCR-12-0690>

Zhang Y, Farenholtz K, Yang Y, Guessous F, Dipierro CG, Calvert V, Deng J, Schiff D, Xin W, Lee J, Purow BW, Christensen JG, Petricoin EF 3rd, Abounader R. Hepatocyte growth factor sensitizes brain tumors to c-Met kinase inhibition. *Clin Cancer Res*. 2013 Feb 5.

<https://doi.org/10.1158/1078-0432.CCR-12-2832>

Godinho MF, Wulfkühle JD, Look MP, Sieuwerts AM, Sleijfer S, Foekens JA, Petricoin EF 3rd, Dorssers LC, van Agthoven T. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib. *Br J Cancer*. 2012 Aug 14. doi: 10.1038/bjc.2012.351.

<https://doi.org/10.1038/bjc.2012.351>

van Agthoven T, Godinho MF, Wulfkühle JD, Petricoin EF 3rd, Dorssers LC. Protein pathway activation mapping reveals molecular networks associated with anti-estrogen resistance in breast cancer cell lines. *Int J Cancer*. 2012 Feb 1

<https://doi.org/10.1002/ijc.27489>

Goudarzi M, Ross MM, Zhou W, Van Meter A, Deng J, Martin LM, Martin C, Liotta L, Petricoin E, Ad N Development of a Novel Proteomic Approach for Mitochondrial Proteomics from Cardiac Tissue from Patients with Atrial Fibrillation. *J Proteome Res*. 2011 Jul 8.

<https://pubs.acs.org/doi/abs/10.1021/pr200108m>

Gioeli D, Wunderlich W, Sebolt-Leopold J, Bekiranov S, Wulfkühle JD, Petricoin EF 3rd, Conaway MR, Weber MJ. Compensatory pathways induced by MEK inhibition are effective drug targets for combination therapy against castration resistant prostate cancer. *Mol Cancer Ther*. 2011 Jun 28.

<https://doi.org/10.1158/1535-7163.MCT-10-1033>

Popova TG, Narayanan A, Lance Liotta L, Petricoin E F III, Bailey C, Kehn-Hall K, and Kashanchi F Reverse-phase phosphoproteome analysis (RPMA) of signaling pathways induced by HTLV-1 infection *Retrovirology* 2011, 8(Suppl 1)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112650/?report=reader>

Anderson T, Wulfkuhle J, Petricoin E, Winslow RL. High resolution mapping of the cardiac transmural proteome using reverse phase protein microarrays. *Mol Cell Proteomics*. 2011 Apr 13. [Epub ahead of print]

<https://dx.doi.org/10.1016%2Fj.molonc.2010.09.003>

Popova TG, Turell MJ, Espina V, Kehn-Hall K, Kidd J, Narayanan A, Liotta L, Petricoin EF, Kashanchi F, Bailey C, Popov SG. Reverse-phase phosphoproteome analysis of signaling pathways induced by rift valley Fever virus in human small airway epithelial cells. *PLoS One*. 2010 Nov 3;5(11):e13805.

<https://doi.org/10.1371/journal.pone.0013805>

Wilson B, Liotta LA, Petricoin E 3rd. Monitoring proteins and protein networks using reverse phase protein arrays. *Dis Markers*. 2010;28(4):225-32.

<https://doi.org/10.3233/DMA-2010-0705>

Younossi Z, Baranova A, Stepanova M, Page S, Calvert V, Afendy A, Goodman Z, Chandhoke V, Liotta L, Petricoin E. Phosphoproteomics Biomarkers Predicting Non-alcoholic Steatohepatitis and Fibrosis. *J Proteome Res*. 2010 May 4.

<https://pubs.acs.org/doi/abs/10.1021/pr100069e>

Popova T, Espina VE, Bailey C, Liotta L, Petricoin E, Popov S. Anthrax infection inhibits the AKT signaling involved in the E-cadherin-mediated adhesion of lung epithelial cells *FEMS Immunol Med Microbiol*. 2009 April E pub ahead of print

<http://images.biomedsearch.com/19416348/fim0056-0129.pdf?AWSAccessKeyId=AKIAIBOKHYOLP4MBMRGQ&Expires=1545177600&Signature=wQyTQV5aMqDIGieJX40d5bwvusk%3D>

Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, Cossman J, Kaldjian EP, Scudiero DA, Petricoin E, Liotta L, Lee JK, Weinstein JN. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. *Mol Cancer Ther*. 2007 Mar;6(3):820-32

<https://doi.org/10.1158/1535-7163.MCT-06-0650>

Woodhouse EC, Fisher A, Bandle RW, Bryant-Greenwood B, Charboneau L, Petricoin EF 3rd, and Liotta LA. *Drosophila* screening model for metastasis: Semaphorin 5c is required for I(2)gl cancer phenotype. *Proc Natl Acad Sci*. 2003 Sep 30;100(20):11463-8.

<https://doi.org/10.1073/pnas.2031202100>

Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, Waltham M, Kouros-Mehr H, Bussey KL, Lee JK, Munson PJ, Petricoin III EF, Liotta LA, and Weinstein JN. Proteomic profiling of the NCI60 cancer cell lines using new high-density 'reverse-phase' lysate microarrays. Proc. Natl Acad Sci. 2003 Nov 25;100(24):14229-34. <https://doi.org/10.1073/pnas.2331323100>